新兴的吸入气溶胶装置和策略：我们将走向何方？

Emerging inhalation aerosol devices and strategies: where are we headed?

机构信息

Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, 2006 NSW, Australia.

Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, 2006 NSW, Australia; Respiratory Technology, Woolcock Institute of Medical Research and Discipline of Pharmacology, Sydney Medical School, The University of Sydney, 2037 NSW. Australia.

出版信息

Adv Drug Deliv Rev. 2014 Aug;75:3-17. doi: 10.1016/j.addr.2014.03.006. Epub 2014 Apr 13.

DOI:10.1016/j.addr.2014.03.006

PMID:24732364

Abstract

Novel inhaled therapeutics including antibiotics, vaccines and anti-hypertensives, have led to innovations in designing suitable delivery systems. These emerging design technologies are in urgent demand to ensure high aerosolisation performance, consistent efficacy and satisfactory patient adherence. Recent vibrating-mesh and software technologies have resulted in nebulisers that have remarkably accurate dosing and portability. Alternatively, dry powder inhalers (DPIs) have become highly favourable for delivering high-dose and single-dose drugs with the aid of advanced particle engineering. In contrast, innovations are needed to overcome the technical constrains in drug-propellant incompatibility and delivering high-dose drugs with pressurised metered dose inhalers (pMDIs). This review discusses recent and emerging trends in pulmonary drug delivery systems.

摘要

新型吸入性疗法，包括抗生素、疫苗和抗高血压药物，推动了合适的给药系统的设计创新。这些新兴设计技术迫切需要确保高雾化性能、一致的疗效和令人满意的患者依从性。最近的振动网和软件技术已经产生了具有显著精确剂量和便携性的雾化器。另一方面，干粉吸入器（DPIs）在借助先进的颗粒工程来输送高剂量和单剂量药物方面变得非常受欢迎。相比之下，需要创新来克服药物-推进剂不相容性和使用压力定量吸入器（pMDIs）输送高剂量药物的技术限制。本文综述了肺部药物输送系统的最新和新兴趋势。